Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer progression or death risk by 26% compared to standard chemotherapy. The ...

Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE ® FL-1 trial Full results from the trial will be ...

The combination of Epkinly and R-mini-CHOP showed a 93% ORR and 86% CR rate in elderly DLBCL patients. At two years, 79% of patients remained in complete response, with a 76% progression-free survival ...

Genmab's Phase III trial of a combination therapy including its bispecific T-cell engager (BiTE) combination, including Epkinly, has met its primary endpoint in adult patients with relapsed or ...

Genmab (GMAB) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership with AbbVie (ABBV), extended patient survival without tumor progression in a late-stage ...

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a ...

Genmab A/S ( Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with ...

COPENHAGEN, Denmark; May 19, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY ™ (epcoritamab-bysp) as the first and only T-cell ...

TheFly reported on July 2 that H.C. Wainwright analyst Raghuram Selvaraju increased the price target on GMAB to $40 from $38 ...

Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in ...